

Supplementary material to article by N. Dursun et al. "Switching from onabotulinumtoxinA to abobotulinumtoxinA in children with cerebral palsy treated for spasticity: A retrospective safety and efficacy evaluation"

Table SI. Mean change from baseline at 4–6 weeks post-injection in Observational Gait Scale (OGS) individual items for the onabotulinumtoxinA (OnaBoNT-A) and abobotulinumtoxinA (AboBoNT-A) treatment cycles

OGS (<i>n</i> = 105)	OnaBoNT-A treatment cycle Mean (SD)	AboBoNT-A treatment cycle Mean (SD)	<i>p</i> -value
Knee position in midstance	0.5 (0.7)	0.4 (0.8)	0.635
Initial foot contact	1.0 (0.7)	0.9 (0.7)	0.096
Foot contact at midstance	0.7 (1.3)	0.6 (0.7)	0.173
Timing of heel rise	1.1 (1.0)	1.1 (0.8)	0.812
Hindfoot at midstance	0.3 (0.7)	0.3 (0.7)	0.892
Base of support	0.5 (0.8)	0.4 (0.7)	0.463
Gait assistive devices	0.2 (0.5)	0.1 (0.5)	0.558
Total score	4.1 (2.2)	3.8 (2.1)	0.202

SD: standard deviation.